Agilent and BTI collaborate to handle a critical want in biopharmaceutical industry The collaboration will address a gap in analytical standards and tests requested drugs predicated on glycoproteins, which form the majority of approved biopharmaceutical drugs right now levitra 5 mg . Current analytical options for characterizing glycans are time-consuming and difficult to deploy in industrial environments. Also, they are limited in their ability to detect and analyze minor glycan species. This collaboration between Agilent and BTI addresses a crucial need in the biopharmaceutical market for a novel technology platform that can support detailed glycan analysis quickly and efficiently in a higher throughput environment, said Nino Totino, general manager for Agilent's Lifestyle Applied and Sciences Marketplaces Group in the South Asia, Korea and Pacific region.
Related StoriesNew era of RNAscope items for RNA-biomarker analysis in FFPE cells releasedOJ Bio at Medica 2015 – Point of Care diagnostics' function in reducing antibiotics prescribingResearchers introduce free iOS app to understand about autism in young children’We are very happy to broaden our relationship with Agilent to advance our scientific platform and our discovery of important small molecules involved in developmental toxicity and autism,’ said Beth Donley, Stemina CEO. ‘We’ve utilized Agilent technology since Stemina began operations in 2007 and also have been happy with the instrumentation, collaboration and support we’ve experienced with Agilent.’ ‘Metabolomics is a significant growth area for all of us, and the innovative work being done at Stemina is the type or kind we prefer to support,’ stated Gustavo Salem, Agilent vice president and general supervisor, Biological Systems Division.